Revesz syndrome revisited

Michael Karremann1*, Eva Neumaier-Probst2, Frank Schlichtenbrede3, Fabian Beier4, Tim H. Brümmendorf4, Friedrich W. Cremer5, Peter Bader6 and Matthias Dürken1

Abstract

Background: Revesz syndrome (RS) is an extremely rare variant of dyskeratosis congenita (DKC) with only anecdotal reports in the literature.

Methods: To further characterize the typical features and natural course of the disease, we screened the English literature and summarized the clinical and epidemiological features of previously published RS cases. In addition, we herein describe the first recorded patient in central Europe.

Results: The literature review included 18 children. Clinical features are summarized, indicating a low prevalence of the classical DKC triad. All patients experienced early bone marrow failure, in most cases within the second year of life (median age 1.5 years; 95% CI 1.4–1.6). Retinopathy occurred typically between 6 and 18 months of age (median age 1.1 years; 95% CI 0.7–1.5). The incidence of seizures was low and was present in an estimated 20% of patients. The onset of seizures was exclusively during early childhood. The Kaplan–Meier estimate of survival was dismal (median survival 6.5 years; 95% CI 3.6–9.4), and none of the patients survived beyond the age of 12 years. Stem cell transplantation (SCT) was performed in eight children, and after a median of 22 months from SCT four of these patients were alive at the last follow up visit.

Conclusion: RS is a severe variant of DKC with early bone marrow failure and retinopathy in all patients. Survival is dismal, but stem cell transplantation may be performed successfully and might improve prognosis in the future.

Keywords: Bone marrow failure, Cerebellar hypoplasia, Exudative retinopathy, Growth retardation, Pancytopenia, Revesz syndrome, Shelterin, Telomere, TINF2

Background

Dyskeratosis congenita (DKC) is a multisystem disorder classically defined by a triad of clinical symptoms including oral leukoplakia, hyperpigmented reticular skin lesions, and nail dystrophy, but the clinical features are highly variable [1, 2]. Individuals are prone to develop bone marrow failure, malignancies, immunodeficiency, and pulmonary complications. Less common features include dental and eye abnormalities, esophageal stenosis, urethral stenosis, avascular necrosis of the femur and/or humerus, osteopenia, enteropathy, and liver disease [3]. Within this wide spectrum of clinical phenotypes, some rare entities represent distinct variants of DKC, namely Høyeraal-Hreidarsson syndrome (HHS, OMIM #305000) and Revesz syndrome (RS; OMIM #268130) [4]. Cerebroretinal microangiopathy with calcifications and cysts (CRMCC; formerly Coats plus syndrome, OMIM #612199) is another disorder of telomere maintenance, with distinct overlap to RS in clinical presentation [5].

Høyeraal-Hreidarsson syndrome is a severe variant of DKC [6]. Patients typically harbor intrauterine growth retardation, microcephaly, and cerebellar hypoplasia. The further course of disease is characterized by developmental delay, and early, progressive bone marrow failure, with the latter leading to death during childhood [7, 8]. First described in 1988 by Tolmie et al. [9, 10], extensive intracranial calcifications, leukodystrophy, and bilateral
exudative retinopathy characterize CRMCC. Other features, including bone marrow failure during adolescence and early adulthood, increased risk of intestinal bleeding and bony lesions have been described [11–14], and may help to clinically discriminate CRMCC from RS [15]. The latter entity was first described in 1992 [16], and is characterized by early bone marrow failure and bilateral exudative retinopathy. It features skin, hair, and nail abnormalities, intracerebral calcifications, cerebellar hypoplasia, and ataxia. In addition, children may be born small for gestational age and exhibit developmental delay. Death usually occurs during early childhood [17–20].

All variants of DKC share dysfunctional telomere maintenance, resulting in a reduced protection from cellular senescence and accelerated exhaustion of (in particular) high turnover tissues, genetic instability, and increased frequency of secondary malignancy. To date, a minimum of 11 genes of the DKC complex have been shown to harbor mutations accounting for the different subtypes of DKC. However, the association of genotype and phenotype is highly variable. While patients with classical DKC harbor mutations in ACD, CTC1, DKC1, NHP2, NOP10, PARN, RTE1, TERC, TERT, TINF2, and WRAP53 [4], several of these mutations may also underly the more severe HHS [6, 21]. In contrast, CRMCC and RS are linked to mutations in distinct genes, namely the CST telomere replication complex component 1 (CTC1), and in the TRF1-interacting nuclear factor-2 (TINF2), respectively [22, 23].

In RS, mutations in TINF2 at chromosome 14q11.2 result in dysfunctional TIN2 protein leading to impaired telomere protection by the shelterin complex [24]. Patients harbor extremely short telomeres, even compared to patients with classical DKC [3, 20]. Mutations in additional genes reported in DKC patients affecting the telomerase complex have not been associated with RS. Nevertheless, the same mutations in TINF2 may be found in classical DKC patients presenting clinically without the distinct RS phenotype, hence, the genotype alone is not able to define RS [20, 25, 26]. Discriminating RS from other variants solely by clinical criteria may also be challenging. Furthermore, the clinical features vary significantly in individual patients, and overlap of RS with other DKC variants [27, 28] or alternate disease entities, such as Fanconi anemia or others, is common [29–32]. In addition, accelerated telomere shortening can also be observed in non-hereditary clonal and non-clonal disorders affecting individual (mostly the hematopoietic) stem cell compartments [33].

To the best of our knowledge, no more than 17 patients with RS, together with sufficient clinical data, have been published in the English literature to date [3, 16–20, 23, 34–42]. Reviewing these cases and reporting the first patient in central Europe, the present work aimed to further characterize this rare entity.

Patients and methods
Mutational and telomere length analysis
The average length of telomere repeats in peripheral blood lymphocytes and granulocytes of the patient (at the age of 15 months), as well as her parents and siblings, was determined by flow-FISH as previously described [43]. Molecular analysis included screening for genetic alterations within exon six of the TINF2 gene.

Literature search
To identify previously published patients with RS, an electronic PubMed search of the English literature was performed using the terms “bone marrow failure”, “aplastic anemia”, and “pancytopenia”, each in combination with “retinopathy”. In addition, PubMed was searched for “Revesz syndrome”, and “TINF2”. Further case reports were included, if referred to in the relevant literature. In case of insufficient clinical information within the publications, the respective corresponding authors were contacted and requested to provide missing data. Individuals who provided further information are mentioned in the acknowledgement section.

Statistical analyses
Statistical analysis was performed using IBM SPSS Statistics® version 25 (IBM, Armonk, NY, USA). Survival, as well as the time-dependent cumulative risk to develop bone marrow failure, retinopathy, and seizures, was estimated by Kaplan–Meier analysis. Patients were censored in case of death, and at the age of the last reported visit. All patients were defined regarding gender (male/female), and potential features of RS (present/absent/unknown). A chi²-test was applied to compare the sex of patients to an equal gender distribution. Due to the small number of patients, the retrospective character of the study, and a potential bias since the underlying case reports might not be representative, the prevalence of these features was discussed cautiously. Statistical numbers are intended to be “hypotheses generating”. Details are given in Table 1.

Results
Case report
The female infant was delivered preterm after 33 gestational weeks (birth weight 1360 g, P10) as the 4th child of non-consanguineous parents with Caucasian descent. Apart from a mild oligohydramnios and suspected growth retardation, pregnancy was uneventful. Delivery and postnatal course were without complication and, in particular, no respiratory support was required.
| Patient number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
|----------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|
| Gender (m/f)   | f | m | f | f | m | m | m | m | m | f  | m  | m  | f  | m  | f  |    |    |    |
| Medical history | – | – | – | – | – | – | – | – | – | +  | –  | +  | –  | +  | –  | ?  | ?  | +  |
| Preterm        | + | + | + | + | + | ?  | –  | –  | +  | +  | +  | +  | –  | +  | +  | ?  | +  | ?  |
| Small for gestational age | + | – | – | + | – | + | – | + | ? | ? | ? | ? | ? | ? | ? | ? | ? | ? |
| Neurologic findings | Microcephaly | 11/2 (13) | + | – | – | + | – | ? | ? | + | + | + | + | + | + | + | + | + |
| Cerebellar ataxia | 3/14 (17) | + | – | + | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Hypoplasia of the cerebrum | 12/5 (17) | + | – | – | + | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Ophthalmologic findings | Exudative retinopathy | 18/0 (18) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Bone marrow failure | 18/0 (18) | + | + | + | + | – | – | – | + | + | + | + | + | + | + | + | + | + |

Table 1: Summary of clinical findings and outcome in 18 patients with RS
Table 1 (continued)

| Ratio: o/r | Duprey and Steger et al. [35] | Revesz Kajtar and Mehes [36] | Riyaz Scheinfeld Negron et al. [38] | Savage and Bertuch [3] | Sasa et al. | Asai et al. [34] | McElnea et al. [37] | Tamura et al. | Gupta et al. | Gupta et al. | Moussa et al. [18] | Tomcikova et al. [41] | Watanabe et al. [42] | Sakwit et al. This report |
|------------|-------------------------------|-------------------------------|-------------------------------------|-----------------------|-------------|------------------|-------------------|----------------|-------------|-------------|-------------------|-------------------|------------------|----------------------------|
|            | Dermatologic                  |                               |                                     |                       |             |                  |                   |                |             |             |                   |                   |                  |                             |
|            | Irregular nails               | +                             | −                                  | +                     | −           | +                | +                 | −              | −           | −           | +                  | −                 | −                | +                           |
|            | Skin findings                 |                               |                                     |                       |             |                  |                   |                |             |             |                   |                   |                  |                             |
|            | Fine, sparse hair             |                               |                                     |                       |             |                  |                   |                |             |             |                   |                   |                  |                             |
|            | Therapy and outcome           |                               |                                     |                       |             |                  |                   |                |             |             |                   |                   |                  |                             |
|            | Stem cell transplantation     |                               |                                     |                       |             |                  |                   |                |             |             |                   |                   |                  |                             |
|            | Last follow up (age/years)    |                               |                                     |                       |             |                  |                   |                |             |             |                   |                   |                  |                             |
|            | Alive                         |                               |                                     |                       |             |                  |                   |                |             |             |                   |                   |                  |                             |
|            | Genetic TINF2 alteration      |                               |                                     |                       |             |                  |                   |                |             |             |                   |                   |                  |                             |

+ prevalent, − absent, ? not determined, # additional information was provided by personal communication
At the age of 2½ months, the girl experienced her first partial seizure following vaccination. MRI imaging revealed cerebellar hypoplasia and periventricular white matter changes, at this time attributed to prenatal hypoxemia (Fig. 1). Due to recurrent seizures, an anticonvulsive treatment with levetiracetam and topiramate was initiated. Pancytopenia was first seen at the age of 9 months, during an episode of bronchitis (leukocytes 2600/µL, hemoglobin 8.7 g/dL, thrombocytes 15,000/µL). Over the next few months, the blood count continued to worsen to very severe neutropenia (absolute neutrophil count < 200/µL), resulting in platelet transfusions twice weekly and erythrocyte transfusions every other week. Diagnostic workup showed bone marrow aplasia without signs of myelodysplasia or cytogenetic abnormalities. Metabolic diseases and infections, as well as Fanconi anemia and paroxysmal nocturnal hemoglobinuria, were ruled out as the underlying pathology for the observed bone marrow failure.

Soon after birth, an exudative retinopathy had been diagnosed and treated with repeated intraocular Bevacizumab injections. Furthermore, the patient exhibited a mild psychomotor developmental delay and a failure to thrive, e.g. body weight of 5 kg (< P3), length of 62 cm (< P3), and head circumference of 40 cm (< P3) at the age of 10 months. In contrast to her siblings, she had fine, sparse hair, but normal skin and nails (nail dystrophy developed by the age of 4 years). A second MRI of the brain at the age of 1 year confirmed cerebellar hypoplasia, but also revealed multiple demyelinating areas, both in the periventricular and subcortical white matter, in part with calcifications (Fig. 2 and Additional file 1: Figure 1). In addition, a distinct hypoplasia of the corpus callosum developed, most likely due to increasing leukencephalopathy (Additional file 2: Figure 2).

The diagnosis of RS was finally suspected based on of the clinical signs and MRI findings. This was confirmed by telomere length analysis, which revealed extremely short telomeres of 2.47 kilobases (kb) in peripheral blood lymphocytes and 2.48 kb in peripheral blood granulocytes, both substantially below the first percentile of healthy controls. Both parents and three siblings exhibited telomere lengths within the normal range (Fig. 3). Mutation analysis detected a genetic alteration in exon six of TINF2 with a previously published base change c.845G > A, leading to the amino acid change Arg282His.

The child underwent allogeneic bone marrow transplantation (SCT) from a healthy HLA-identical sibling at the age of 17 months. The conditioning regimen included fludarabine (30 mg/m² day −7 to −3), cyclophosphamide (30 mg/kg day −6 to −3), and anti-thymocyte globulin (20 mg/kg day −4 to −2). Apart from an invasive aspergillosis of the lungs and a mild acute graft-versus-host disease, no serious complications occurred. Hematological engraftment was achieved after day +11, and day +55 for granulocytes and thrombocytes, respectively. The girl exhibited an early T-cell expansion with >500 CD3+ cells/mL at day +60. A reactivation of Adenovirus detected by PCR at day +70 resolved spontaneously. Aspergillus infection was treated with intravenous liposomal amphotericin B and caspofungin, followed by an oral treatment with voriconazole until 10 months from SCT, resulting in residual lesions in both upper pulmonary lobes. Further mild and non-persisting complications within the first year from SCT included Epstein-Barr virus reactivation (treated by one single

![Fig. 1](initial MRI at the age of 2.5 months performed after the first partial seizure. Sagittal T1-weighted MRI image demonstrates cerebellar hypoplasia with an emphasis on the vermis and tonsils (arrow) and consecutive enlargement of the cerebrospinal fluid (CSF) spaces. The corpus callosum has a normal shape and size (thick arrow) (a). Transversal T1-weighted MRI image shows normal myelination within the internal capsule concealing the punctuate high signal (b) corresponding to the low signal areas in the T2-weighted (c) and T2*-weighted images within the thalami (d). These areas of signal abnormality correspond to calcifications. Also note the abnormal signal intensity in the frontal lobes (b, c) corresponding to leukencephalopathic areas also seen in the follow ups. At this point there was no administration of gadolinium contrast material.
Fig. 2 Axial T2-weighted images demonstrate progression of symmetric white matter lesions periventricular, within the thalamus, in the internal capsule, and the basal ganglia at the age of 1 year (a), 2 years (b), and 3.8 years (c). The corresponding axial susceptibility-weighted images (SWI) demonstrated progressive foci with susceptibility artefacts distributed symmetrically within the basal ganglia, the thalami, and on the border between gray and white matter (d, e), corresponding to calcifications. At the age of 2 years the patient suffered from a hemorrhage at the level of the left temporal horn with intraventricular breakthrough, shown as an area of high intensity (arrow) on the T1-weighted image (f), and hydrocephalic congestion (b, f), resulting in the need for ventricular-peritoneal shunt insertion. The artefact on the right side is due to the implanted shunt (c).

Fig. 3 Telomere length analysis of the patient (red), her siblings (yellow), and parents (blue) demonstrates the shortening in the patient’s a lymphocytes and b granulocytes, substantially below the first percentile of age. In contrast, the results of her parents and siblings were within normal limits. c Pedigree. Circle indicates female, square indicates male gender.
From BMF in most cases, but refractory lung failure was another cause of death in some cases. Bone marrow failure occurred in all patients between birth and the age of 6 years, in most cases within the second year of life (median age 1.5 years; 95% CI 1.4–1.6, Fig. 5a).

BMF lead to stem cell transplantation in eight patients, four of whom were still alive at the end of follow up 1 month (#3), 20 months (#9), and 2 years (#14 and #16) from SCT. Details on the conditioning regimen were specified in four patients; all underwent a reduced conditioning regimen, including fludarabine (100–180 mg/m²), cyclophosphamide (100–120 mg/kg), and anti-thymocyte globulin. Patients with this regimen tolerated SCT well without severe early transplantation-related toxicity. All patients developed retinopathy, most likely between the ages of 6 and 18 months (median age 1.1 years; 95% CI 0.7–1.5; Fig. 5b). Despite treatment, retinopathy led to a severe loss of visual acuity in most patients. Glaucoma occurred in three cases. Frequent features of RS include neurological and neuroanatomical abnormalities. In the present cohort, cerebellar hypoplasia (76%, n = 13/17) and intracranial calcifications (85%, n = 11/13) were common features, whereas microcephalia and ataxia were reported less often (Table 1). Only three patients (unknown in one) experienced seizures, that developed exclusively during early childhood, resulting in a cumulative incidence rate of 20% (SD 10.7; Fig. 5c). Our study substantiated neurodevelopmental delay and/or mental retardation to be a frequent feature of RS, and this was present in 71% of patients (n = 12/17), frequently emerging during infancy. However, learning deficits were often mild, and absent in others, indicating that neurocognitive impairment is not an obligatory feature of the syndrome. Of note, intracranial hemorrhage was detected in three patients during the course of the disease and might represent a yet underrecognized cerebrovascular vulnerability. Patients with RS are born small for gestational
age and/or preterm, resulting in a mean birth weight of 1950 g ± 410 (SD), and one out of three patients failed to thrive (Table 1).

Genetic mutational analysis was available in 66% of patients (n = 12) and was performed in all patients that were published since 2010. All of these harbored a TINF2 mutation and the underlying alterations were restricted to exon six. The most frequent mutation was c.845G > A, a missense mutation resulting in an amino acid substitution of Alanine to Histidine at position 282 of the TIN2 protein. Further mutations included two heterozygous deletions resulting in a frameshift and premature stop codon leading to truncated TIN2 proteins (c.839delA, p.K280fsX36, patient #9; and c.851-855 del CAGTC; p.T284Nfsx, patient #17) and alternate missense mutations at position 284 (c.850A > C; p.T284P; patients #12, 13) and 289 (c.865C>T, p.P289S, patient #15) of the TIN2 protein. Hence, all mutations were located between amino acid 280 and 289.

Telomere analysis was available in seven patients. All presented with very short lengths, reported as “below the first percentile for their age” (patients #10, #12, #13, #20), reported in absolute numbers of 2.3–2.8 kb (#8) and 2.5 kb (#20) and/or given as relative shortening of −5.7 SD (#16).

Discussion

Revesz syndrome is an extremely rare disorder, and to date, patients have only been published anecdotally. Therefore, the present work aimed at further characterization of this rare entity by summarizing the clinical findings of 17 previously published cases of RS [3, 16–20, 23, 34–42], and presenting the one further case reported in this work. The latter represents the first published patient from central Europe.

Medical history and clinical signs

In the present cohort, we found a slight and non-significant male predominance. This is far less pronounced compared to DKC, with its often X-linked inheritance [2]. Given the autosomal background in RS, we would agree with Gupta and coworkers who state an equal gender distribution in RS [17]. In all, our findings argue against previous presumptions of a considerable male predominance of 3:1 [18].

Looking into the patients’ medical history, growth retardation, either prevalent at birth or a failure to thrive was prevalent in most cases. Four children were delivered preterm, and of note, those did not present small for gestational age. Unfortunately, information on further somatic development was available for only one of these children, and this girl experienced severe failure to thrive soon after birth, indicating that growth retardation starts during late pregnancy or postnatally. However, some children regained underweight. Hence, growth retardation is common, but not a general trait in patients with RS.

Nail dystrophy was the most frequent feature of the clinical DKC triad. In line with findings in classical DKC, typical skin pigmentation and oral leukoplakia were even less frequent [44], resulting in the complete clinical triad

![Fig. 5 Estimated cumulative incidence of various features of RS: a All patients developed bone marrow failure (BMF) by the age of 6 years. Time of diagnosis was available in 16 patients, with BMF occurring most frequently in the second year of life (median age 1.5 years; 95% CI 1.4–1.6). b Accordingly, retinopathy was present in all cases (time of diagnosis was available in 15 patients). Most children developed retinopathy between the ages of 6 and 18 months of life (median age 1.1 years; 95% CI 0.7–1.5). c Only three patients (unknown in two) experienced seizures. These developed exclusively during early childhood, resulting in an estimated cumulative incidence rate of 20% (SD 10.7).](image-url)
in only two cases, in contrast to 35% in DKC [44]; hence, the clinical signs of the DKC triad seem less common in patients with RS [45]. This might be confusing, since the prevalence of these correlate with a more severe course of the disease and early onset BMF in classical DKC [4, 44]. However, the seemingly low incidence in RS is in line with previous assumptions [26] and might well be due to the young age at diagnosis and early death of these patients, since the DKC triad may develop with age and sometimes following BMF [4, 45] between the ages of five and 13 years [2, 46]. Accordingly, in patients #11 and #18 of our cohort, nail dystrophy was absent when the diagnosis of RS was made but developed during course of disease. Furthermore, this review might underestimate the prevalence, since findings may be subtle and not all case reports commented on these signs. We would therefore suggest careful screening for signs of the DKC triad in patients with suspected RS, not only at time of initial diagnosis but also at older ages. However, diagnosis of RS is based on additional features and a lack of DKC signs, especially in young children, should not preclude from providing a diagnosis [4].

As in DKC, patients with RS may be prone to developing secondary malignancies [47]. Most likely due to the short survival time, none of the patients from the present report experienced such complications. However, once survival might improve, patients should be monitored accordingly.

Bone marrow failure
TINF2 mutations have been linked to severe BMF [48]. Accordingly, BMF, occurring at an even younger age than previously suspected, is a general trait of RS [18]. Reflecting the most severe course of disease, BMF was most likely to develop within the second year of life and, in all cases, developed by the age of 6 years (Fig. 5a).

Stem cell transplantation (SCT) was performed in eight patients from the present cohort, and four of these were still alive at the last documented visit. Hence, SCT should be offered to patients, if required clinically, potentially resulting in improved survival in the future. Various conditioning regimens, stem cell sources, and donors have been published [3, 18, 20, 34, 36, 40, 42]. The authors point out a relevant treatment-related toxicity due to the underlying telomere disorder (particularly affecting the lung), and the approach should take into account experiences in DKC patients. In this regard, Ostonoff suggested a reduced intensity conditioning (RIC) regimen including fludarabine, cyclophosphamide, and anti-thymocyte globulin in DKC patients [49]. Within the present cohort, four of the eight cases, including our patient, underwent this regimen with only limited acute SCT-associated toxicity [34, 40, 42]. Hence, we suggest applying this conditioning regimen in patients with RS, but still SCT in RS remains a high-risk transplantation and should, therefore, be carried out by experienced centers only.

Pulmonary disease
Lung complications contribute to treatment-related mortality, especially following SCT in adult DKC patients [46, 48, 50]. Accordingly, two deaths in this series occurred due to terminal lung failure 2 years [this report] and 4.5 years [40] after the date of the successful SCT. Conditioning regimens with potential pulmonary toxicity should, therefore, be avoided to prevent worsening of occult lung disease [42, 51]. Given that pulmonary interstitial fibrosis is independently attributed to TINF2 mutations [49, 52, 53], lung disease due to insufficient telomere maintenance may be regarded as an obligatory late sequela in patients with RS also without SCT [52]. Accordingly, in DKC, sporadic lung disease may develop within the second and third decade, but with a median of 4.7 years following SCT [53]. Only one of the 10 cases without SCT in the present review experienced lung failure (at the age of 12 years), most likely due to the short survival time of the others [38]. Therefore, this complication should not preclude from performing SCT, but patients should be educated and monitored accordingly. Potentially, early and aggressive interventions in case of respiratory symptoms might further improve survival (especially following SCT) in the future.

Retinopathy
In the present study, exudative retinopathy occurred during infancy and early childhood, most likely between the ages of 6 and 18 months (Fig. 5b). Some children were born preterm, but the medical history was unlikely to determine an association between retinopathy and prematurity. Hence, RS should be considered in case of Coats-like retinopathy in infants without a typical history. Therapy included photocoagulation [17, 18, 20, 23, 34, 37, 41], repeated bevacizumab injections [17, 34], retinocryopexia [35, 36], and surgical approaches, including vitrectomy [17, 34, 37, 41] and enucleation, in cases of complete loss of visual acuity with or without painful glaucoma [16, 36, 41]. To date, laser photocoagulation is the preferred mode of therapy, and bevacizumab injections are an alternative [50]. However, in RS-associated retinopathy, most patients will develop a severe loss of visual acuity despite treatment.

Exudative retinopathy is a defining trait of RS [4]. However, there is a huge overlap to alternate entities that may harbor other features of RS, including BMF, failure to thrive, mental retardation, and the cerebral abnormalities. These include patients with DKC and potentially
mutations other than TINF2, in whom retinopathy may occur occasionally [28, 51, 54, 55]. These patients may be discriminated from RS by the less severe course of disease and/or the absence of a TINF2 mutation. In addition, in cases of a familial history of DKC, the diagnosis of RS should be questioned. HHS may be associated with retinopathy [27], mimicking the severe course of RS. However, a familial history of DKC and mutations outside TINF2 may exclude RS and classify these patients as HHS. Moreover, a relevant overlap is found with CRMCC. This disease, formerly called Coats plus syndrome, resembles RS regarding bilateral exudative retinopathy, intracranial calcifications, mucocutaneous abnormalities, and bone marrow failure. It can be discriminated by molecular analysis, since CRMCC is restricted to CT11 mutations. Clinically, it differs from RS by the prevalence of bony lesions and intestinal bleeding [11–14]. Since SCT is dispensable due to the late onset and often mild course of BMF, discriminating CRMCC from RS is of utmost importance [15]. Further disorders include Fanconi anemia [31, 32, 56] and rare entities, including mutations in DNAJC21 and ERCC6L2 [29, 30].

Conversely, patients with features of RS including early onset of BMF and TINF2-mutations but lacking exudative retinopathy are published in the literature. These cases differ from RS not only in terms of the ophthalmologic findings, but they also usually exhibit a less progressive course and longer survival. These patients should not be classified as RS [3], but represent variants of autosomal dominant DKC [57–59]. Therefore, accurate clinical evaluation, including verification or exclusion of retinopathy, is essential to classify the disease properly and thereby enabling clear decisions on best possible treatment of the patient.

Central nervous system (CNS) manifestation
Cerebral calcifications is a central trait of RS [4, 46], reported in all but two patients with clinical information. Hence, even if calcifications may be seen in other entities, including CRMCC, HS, and DKC, this feature in combination with retinopathy, early onset of BMF, and the molecular evaluation of TINF2 is a valuable predictor of RS. Therefore, diagnosis of RS in the absence of cerebral calcifications should be based on other strong criteria. Microcephaly and cerebellar hypoplasia were less common. The latter is usually attributed to HHS [21]. However, cerebral abnormalities are common in TBD and seem to widely overlap between the various DKC variants, with none being specific for a distinct entity [60]. In this regard, we describe the first patient with RS and a hypoplastic corpus callosum. Of note, given that the first MRI soon after birth revealed normal findings, we would hypothesize that the hypoplasia may be attributed to leukoencephalopathy, and the rarity of this trait in RS may be due to the short life expectancy in most patients. In this regard, involution of the corpus callosum may be a general feature in TBI, as it has been described in various patients with HHS [61]. Rarely, gliotic lesions may occur [23].

Of note, three patients of the present cohort experienced intracranial hemorrhages resulting in relevant morbidity [19, 38]. These bleeds might have been associated with cerebrovascular fragility rather than with low platelets or a plasmatic bleeding predisposition, since cerebral bleeding has been reported in other patients with TINF2 mutations [58], and bleeding from telangiectasias including gastrointestinal hemorrhages is a common trait of other telomere biology disorders [50]. Negron and coworkers hypothesized that reabsorption and healing of such cerebral (micro)bleedings might result in calcifications and, hence, be a pathophysiological trigger of this frequent feature in RS [38].

Scheinfeld has summarized neuroradiologic findings in RS [23]. Herein, we provide further paradigmatic NMR imaging findings.

Neurodevelopmental delay is common in RS, but symptoms may be mild, with “satisfying” neurocognitive development [36], or absent in some patients. In fact, one of the patients was a “good student with above-average intelligence and a skillful violin player” [38]. However, early and repeated neurodevelopmental assessment is indispensable in patients with RS and adequate treatment is essential in cases of pathological delay. Despite the numerous cerebral abnormalities, only few patients experienced seizures, and these developed exclusively during early childhood (Fig. 5c). Hence, in line with other telomere biology disorders [46], epilepsy may occur occasionally, but is not a typical feature of RS.

Genetic background and telomere biology
RS is a telomere biology disorder (TBD) within the DKC spectrum resulting in impaired telomere maintenance [62]. The principles of TBD have been summarized by Barbaro, who focused on the various clinical entities [46], whereas Smith has extensively reviewed the biochemical background of telomere maintenance [24].

In contrast to DKC, RS is restricted to mutations in one single gene, namely TINF2 on chromosome 14q12 [46]. Five different mutations have been published to date, all affecting exon six, similar to all TINF2 mutations described in DKC. The most common germline alteration is c.845G > A, a missense mutation with substitution of guanine to adenine, leading to an amino acid substitution from arginine to histidine at position 282 of the TIN2 protein. Further mutations have been found sporadically that are summarized in Table 1 [17, 19, 34, 41].
Dysfunctional TIN2 results in an impaired protection of telomere ends by the shelterin complex and patients harbor extremely short telomeres. Hence, premature shortening of telomere repeats leads to premature cell senescence [62]. Regarding the variant molecular interactions of the mutant TIN2 protein with its natural ligands, the readers are referred to the respective literature [63–65]. It is still under debate whether the extent of telomere shortening is generally associated with the severity of symptoms [66, 67]. Undoubtedly, extremely short telomeres in RS, even compared to other TBD, correlate with a more severe course as well as the early onset of this disorder.

It is noteworthy that not all alterations in TINF2 are pathogenic, hence polymorphisms of the gene exist [66]. Conversely, most patients with TINF2 mutations develop TBDs other than the classical phenotype of RS, including not only 11 to 24% of DKC patients [3, 20, 46], but also HH5, idiopathic pulmonary fibrosis, and aplastic anemia [20, 21, 48, 68, 69]. Even the most frequent TINF2 mutation, p.R282H, is not specific for RS and it is yet unclear which additional mechanisms lead to its full phenotype.

Recently, TIN2 was identified as a modifier of telomerase activity via interaction with TPP1/POT1, representing an alternate mechanism of telomere pathology in TINF2 mutations [70], and failure to restore telomere length during early pregnancy was hypothesized to contribute to very short telomeres in severe variants [67]. In addition, varying gene expression within different tissues may be related to clinical phenotypes [17], but there is still much effort required to elucidate the pathogenic biological mechanisms. Therefore, at the present time, clinical features, a mutation within exon six of TINF2, and very short telomeres, e.g. below the first percentile of age, are needed to make an accurate diagnosis.

Conclusion

We present a comprehensive review on Revesz syndrome by studying previously published patients, in addition to an individual case report first presented here. In summary, RS is characterized by an early onset of exudative retinopathy and bone marrow failure, as well as a very poor survival. Features of the DKC triad, cerebral calcifications, growth retardation, and neurodevelopmental delay are part of the disease in most but not all cases. In addition, we report the first patient from central Europe, who in contrast to all previously published cases, developed hypoplasia of the corpus callosum during early childhood. Since TINF2 mutations are not restricted to RS, clear definition of clinical features is essential for an adequate diagnosis, but symptoms overlap with other entities. Therefore, clinical registries and further genetic studies are needed to elucidate the molecular background of this rare disorder as well as support the exploration of novel therapeutic strategies aiming at improved telomere maintenance [71].

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s13023-020-01553-y.

Acknowledgements

We greatly acknowledge Shinichi Tamura and Dana Tomcikova for providing additional clinical information on patients #11 and #15, respectively.

Authors’ contributions

MK was responsible for study concept, literature review, and wrote the manuscript. E.N.P. provided neuroradiological imaging and F.B. performed telomere length analysis and provided Fig. 3. F.S., T.B., F.C., P.B., and M.D. critically reviewed the manuscript for important intellectual content. All authors have read and approved the final version of the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. The authors declare no specific grant was awarded for this research from any funding agency.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The present study has been approved by the Institutional Review Board II, Medical Faculty Mannheim, Heidelberg University (2020-832R).

Consent for publication

The patient described in this manuscript finally died in 2014. Since then, her parents have not visited our hospital again, and we have failed to contact them recently to ask for their consent to the present publication. No identifiable photos of the child have been added to the manuscript, and due to the huge catchment area of our hospital, including a population of approximately two million citizens, identification of the family by the clinical description seems largely excluded. We, however, hope that the case description as well as the representative neuroradiological imaging and the impressive figure concerning telomer shortening may remain in the present review.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Pediatrics, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. 2 Department of Neuroradiology, University Medical Center Mannheim, Mannheim, Germany.
39. Riyaz A, Riyaz N, Jayakrishnan MP, Mohamed Shirs PT, Ajith Kumar VT, Ajith BS. Revesz syndrome. Indian J Pediatr. 2007;74(9):862–3.
40. Tamura S, Inamura T, Ura T, Kobayashi M, Gen M, Tomi T, Do J, Osone S, Ishida H, Hosoi H, Kuroda H. Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita: a report of 3 cases. J Pediatr Hematol Oncol. 2013;39(7):e934–8.
41. Tomickova D, Gerinec A, Busanyova B, Greskova M, Biskup S, Hertogel K. Why is it necessary to examine retina when the patient suffers from aplastic anemia? Bratisl Lek Listy. 2018;119(5):275–7.
42. Watanabe K, Arakawa Y, Kambe T, Oguma E, Kishimoto H, Koz K. Unrelated allogeneic hematopoietic stem cell transplantation in a patient with Revesz syndrome, a severe variant of dyskeratosis congenita. Pediatr Blood Cancer. 2019.66(1):e27476.
43. Ferreira MSV, Kirschner M, Halfmeyer I, Estrada N, Xicoay B, Isfort S, Vieri M, Zamora L, Abels A, Bouillon AS, Begemann M, Schromnneik M, Mauer U, Koschmieder S, Wilop S, Panse J, Brummendorf TH, Beier F. Comparison of flow-FISH and N and qPCR telomere length assessment techniques for the screening of telomeropathies. Ann N Y Acad Sci. 2020;1466(1):93–103.
44. Ward SC, Savage SA, Giri N, Alter BP, Rosenberg PS, Pichard DC, Cowen EW. Beyond the triad: inheritance, mucocutaneous phenotype, and mortality in a cohort of patients with dyskeratosis congenita. J Am Acad Dermatol. 2018;78(4):804–6.
45. Dokal I. Dyskeratosis congenita. Hematol Am Soc Hematol Educ Program. 2011;2011:480–6.
46. Barbaro PM, Ziegler DS, Reddel RR. The wide-ranging clinical implications of the short telomere syndromes. Intern Med J. 2016;46(4):393–403.
47. Walsh MF, Chang VY, Kohlmann WK, Scott HS, Cunniff C, Bourdeaut F, Walsh MF, Chang VY, Kohlmann WK, Scott HS, Cunniff C, Bourdeaut F, Centonze D, Cendron M, Gluzman Y, Nevecourt T, et al. Structural and functional analyses of the mammalian TIN2-TPP1-TRF2 telomeric complex. Cell Res. 2017;27(12):1485–502.
48. Ostronoff F, Ostronoff M, Calixto R, Florencio R, Domingues MC, Souto CH. Revesz syndrome. Indian J Pediatr. 2007;74(9):862–3.
49. Tamura S, Ito S, Mihalek A, Iwaki M, Hata F, Ito S, Mihalek A, Iwaki M, Hata F, Ikebuchi Y, et al. Beyond the triad: inheritance, mucocutaneous phenotype, and mortality in a cohort of patients with dyskeratosis congenita. J Am Acad Dermatol. 2018;78(4):804–6.
50. Higgs C, Crow YJ, Adams DM, Chang E, Hayes D Jr, Herbig U, Huang JN, McReynolds LJ, Nelson A, Olson T, Pariser A, Perona R, Sasa G, Schratz K, Tsilou ET, Giri N, Helms Guba L, Khincha PP, Lin TF, Longhurst H, et al. Telomere biology disorders. Angiogenesis. 2019;22(1):95–102.
51. Mason JO 3rd, Yunker JJ, Nixon PA, Vail RS, Tsilou E, Giri N, Alter BP. Prognostic significance of pulmonary function tests in dyskeratosis congenita and TINF2 mutation of shelterin complex involved in the telomere maintenance and its association with disease mutations. Cells. 2020;9(2):359.
52. Hu C, Rai R, Huang C, Broton C, Long J, Xu Y, Xue J, Lei M, Chang S, Chen Y. Structural and functional analyses of the mammalian TIN2-TPP1-TRF2 telomeric complex. Cell Res. 2017;27(12):1485–502.
53. Nelson ND, Dodson LM, Escudero L, Sukumar AT, Williams CL, Mihalek I, Baldan A, Baird DM, Bertucc AA. The C-Terminal extension unique to the long isoform of the shelterin component TIN2 enhances its interaction with TRF2 in a phosphorylation- and dyskeratosis congenita cluster-dependent fashion. Mol Cell Biol. 2018;38(12):e00025–18.
54. Vulliamy T, Beswick R, Kirwan MJ, Hossain U, Walne AJ, Dokal I. Telomere length measurement can distinguish pathogenic from non-pathogenic variants in the shelterin component TINF2. F1000Res 2018;7:524.
55. Amir M, Khan P, Queen A, Dobane R, Almajf MF, Hussain A, Islam A, Ahmad F, Hassan I. Structural features of nucleoprotein CST/shelterin complex involved in the telomere maintenance and its association with disease mutations. Cells. 2020;9(2):359.
56. Higgs C, Crow YJ, Adams DM, Chang E, Hayes D Jr, Herbig U, Huang JN, McReynolds LJ, Nelson A, Olson T, Pariser A, Perona R, Sasa G, Schratz K, Tsilou ET, Giri N, Helms Guba L, Khincha PP, Lin TF, Longhurst H, et al. Telomere biology disorders. Angiogenesis. 2019;22(1):95–102.
57. Mason JO 3rd, Yunker JJ, Nixon PA, Vail RS, Tsilou E, Giri N, Alter BP. Prognostic significance of pulmonary function tests in dyskeratosis congenita and TINF2 mutation of shelterin complex involved in the telomere maintenance and its association with disease mutations. Cells. 2020;9(2):359.
58. Keel SB, Scott A, Sanchez-Bonilla M, Ho PA, Gulsuner S, Pritchard CC, Abkowitz JL, King MC, Walsh T, Shimamura A. Genetic features of myelodysplastic syndrome: Fanconi anemia and dyskeratosis congenita. Ophthalmol Genet. 2019;5(6):370.
59. Akaboshi S, Yoshimura M, Hara T, Kageyama H, Nishikawa K, Kawakami T, Isehima A, Takeshita K. A case of Hoyeraal-Hreidarsson syndrome: delayed myelination and hypoplasia of corpus callous are other important signs. Neuropediatrics. 2000;31(3):141–4.
60. Bhala S, Best AF, Giri N, Alter BP, Pao M, Gropman A, Baker EH, Savage SA. CNS manifestations in patients with telomere biology disorders. Neurol Genet. 2019;5(6):370.
61. Tsangaris E, Adams SL, Yoon G, Chitayat D, Lansdorp P, Dokal I, Dror Y. Ataxia and pancycopenia caused by a mutation in TINF2. Hum Genet. 2008;124(5):507–13.
62. Akaboshi S, Yoshimura M, Hara T, Kageyama H, Nishikawa K, Kawakami T, Isehima A, Takeshita K. A case of Hoyeraal-Hreidarsson syndrome: delayed myelination and hypoplasia of corpus callous are other important signs. Neuropediatrics. 2000;31(3):141–4.
63. Amir M, Khan P, Queen A, Dobane R, Almajf MF, Hussain A, Islam A, Ahmad F, Hassan I. Structural features of nucleoprotein CST/shelterin complex involved in the telomere maintenance and its association with disease mutations. Cells. 2020;9(2):359.
64. Hari C, Rai R, Huang C, Broton C, Long J, Xu Y, Xue J, Lei M, Chang S, Chen Y. Structural and functional analyses of the mammalian TIN2-TPP1-TRF2 telomeric complex. Cell Res. 2017;27(12):1485–502.
65. Nelson ND, Dodson LM, Escudero L, Sukumar AT, Williams CL, Mihalek I, Baldan A, Baird DM, Bertucc AA. The C-Terminal extension unique to the long isoform of the shelterin component TIN2 enhances its interaction with TRF2 in a phosphorylation- and dyskeratosis congenita cluster-dependent fashion. Mol Cell Biol. 2018;38(12):e00025–18.
66. Vulliamy T, Beswick R, Kirwan MJ, Hossain U, Walne AJ, Dokal I. Telomere length measurement can distinguish pathogenic from non-pathogenic variants in the shelterin component TINF2. F1000Res 2018;7:524.
67. Alter BP, Rosenberg PS, Giri N, Baerlocher GM, Lansdorp PS, Savage SA. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica. 2012;97(3):353–9.
68. Keel SB, Scott A, Sanchez-Bonilla M, Ho PA, Gulsuner S, Pritchard CC, Abkowitz JL, King MC, Walsh T, Shimamura A. Genetic features of myelodysplastic syndrome: Fanconi anemia and dyskeratosis congenita. Ophthalmol Genet. 2019;5(6):370.
69. Hoffman TW, van der VisJJ, van Oosterhout MF, van Es HW, van Kessel G, Grutters JC, van Moorsel CH. TINF2 gene mutation in a patient with pulmonary fibrosis. Case Rep Pulmonol. 2016;2016:1301862.
70. Pike AM, Strong MA, Ouyang JPT, Greider CW. TIN2 functions with TPP1/POT1 to stimulate telomerase processivity. Mol Cell Biol. 2019;39(21):e00593–18.
71. Townsley DM, Dumitriu B, Liu D, Biancott A, Weinstein B, Chen C, Hardy N, Mihalek AD, Lingala S, Kim YJ, Yao J, Jones E, Gochuico BR, Heller T, Wu CO, Calado RT, Scheinkarn P, Young NS. Danazol treatment for telomere diseases. N Engl J Med. 2016;374(20):1922–31.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.